Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - ENDO HEALTH SOLUTIONS INC. | d305053d8k.htm |
 ENDO
PHARMACEUTICALS Citi Healthcare Conference
February 27, 2012
Exhibit 99.1
grow. collaborate. innovate.
thrive. |
 grow.
collaborate. innovate. thrive. ©2011 Endo Pharmaceuticals Inc.
2
FORWARD LOOKING STATEMENTS
This presentation contains forward-looking statements within the meaning of the Private
Securities Litigation
Reform
Act
of
1995.
Statements
including
words
such
as
“believes,”
“expects,”
“anticipates,”
“intends,”
“estimates,”
“plan,”
“will,”
“may,”
“look forward,”
“intend,”
“guidance,”
“future”
or similar
expressions are forward-looking statements. Because these statements reflect our
current views, expectations and beliefs concerning future events, these
forward-looking statements involve risks and uncertainties. Investors should note
that many factors, as more fully described under the caption “Risk
Factors”
in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange
Commission and as otherwise enumerated herein or therein, could affect our future
financial results and could cause our actual results to differ materially from those
expressed in forward-looking statements contained in our Annual Report on Form
10-K. The forward-looking statements in this presentation are qualified by
these risk factors. These are factors that, individually or in the aggregate, could cause our
actual results to differ materially from expected and historical results. We assume no
obligation to publicly update any forward-looking statements, whether as a result
of new information, future developments or otherwise. |
 grow.
collaborate. innovate. thrive. ©2010 Endo Pharmaceuticals Inc.
3
Sustaining our Growth
($MM)
SOLID TRACK RECORD OF SALES GROWTH
ENDO EXPECTS TO REPORT MORE THAN $3 BILLION IN 2012 SALES
|
 grow.
collaborate. innovate. thrive. ©2010 Endo Pharmaceuticals Inc.
STRONG CASH FLOW GENERATION
4
$-
$100
$200
$300
$400
$500
$600
$700
$800
$366
$356
$295
$454
$702
Net Cash Provided By Operating Activities
($MM) |
 grow.
collaborate. innovate. thrive. ©2010 Endo Pharmaceuticals Inc.
5
DIVERSIFIED HEALTHCARE SOLUTIONS COMPANY
*Pro forma -
TTM as of 12/31/2011. Includes full year of AMS and Qualitest.
**The
services
segment
does
not
include
the
pro
forma
impact
of
pre-acquisition
revenues
from
the
recently
acquired
electronic
medical
records
providers,
Intuitive
Medical
Software
(IMS)
and
meridian
EMR,
Inc.
Endo -
2008
Endo -
2011
Branded Pharmaceuticals
Generics
Branded Pharmaceuticals
Generics
Devices
Services**
Revenue Mix*
Revenue Mix
93%
7%
56%
19%
18%
7% |
 grow.
collaborate. innovate. thrive. ©2010 Endo Pharmaceuticals Inc.
6
2012 ENDO GUIDANCE
Guidance
Revenue range
$3.15B -
$3.30B
Adjusted diluted EPS range
$5.00 -
$5.20
Reported (GAAP) diluted EPS range
$2.60 -
$2.80 |
 grow.
collaborate. innovate. thrive. ©2010 Endo Pharmaceuticals Inc.
2012 VALUE CREATION OPPORTUNITIES
Successfully launch new formulation of Opana ER
Support the future growth of Qualitest
Invest capital to capture growing demand for products
Exceed cost synergies assumed at time of Qualitest acquisition
Invest in AMS to accelerate growth
AMS/Endo pilot program updates in first half 2012
Invest in R&D to accelerate advance of new products to market
Maximize operating cash flow to pay down debt
Expect ~$500M of cumulative debt repayments to be completed by end of
Q1 2012 on our existing Term Loan indebtedness
7 |
 ENDO
PHARMACEUTICALS grow. collaborate. innovate. thrive. |
 grow.
collaborate. innovate. thrive. ©2010 Endo Pharmaceuticals Inc.
9
9
RECONCILIATION OF NON-GAAP MEASURES
9
For an explanation of Endo’s reasons for using non-GAAP measures, see Endo’s
Current Report on Form 8-K filed today with the Securities and Exchange Commission
Reconciliation of Projected GAAP Diluted Earnings Per Share to Adjusted Diluted Earnings Per
Share Guidance for the Year Ending December 31, 2012 Lower End of Range
Upper End of Range
Projected GAAP diluted income per common share
$2.60
$2.80
Upfront and milestone-related payments to partners
$0.76
$0.76
Amortization of commercial intangible assets and inventory step-up
$1.89
$1.89
Acquisition and integration costs related to recent acquisitions.
$0.10
$0.10
Interest expense adjustment for ASC 470-20 and other treasury
related items
$0.21
$0.21
Tax effect of pre-tax adjustments at the applicable tax rates and
certain other expected cash tax savings as a result of recent
acquisitions
($0.56)
($0.56)
Diluted adjusted income per common share guidance
$5.00
$5.20
The company's guidance is being issued based on certain assumptions including:
•Certain of the above amounts are based on estimates and there
can be no assurance that Endo will achieve these results
•Includes all completed business development transactions as of
February 27, 2012 |
 ENDO
PHARMACEUTICALS Citi Healthcare Conference
February 27, 2012
grow. collaborate. innovate.
thrive. |